<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262184</url>
  </required_header>
  <id_info>
    <org_study_id>GE-PP02</org_study_id>
    <nct_id>NCT00262184</nct_id>
    <nct_alias>NCT00154908</nct_alias>
  </id_info>
  <brief_title>A Taiwan Isoflavone Multicenter Study (TIMS)</brief_title>
  <official_title>A Taiwan Isoflavone Multicenter Study (TIMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taiwan Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genovate Biotechnology Co., Ltd.,</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <brief_summary>
    <textblock>
      Consumption of soy-based foods is associated with a number of health benefits, including&#xD;
      lower risk of cardiovascular disease, breast and prostate cancer, attenuated menopausal&#xD;
      symptoms and prevention of bone loss with age.&#xD;
&#xD;
      In order to investigate the effect of isoflavone on bone mineral density (BMD) and in Taiwan&#xD;
      women with postmenopausal osteopenia, a Taiwan Isoflavone Multicentric Enrollment Study&#xD;
      (TIMS) is designed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consumption of soy-based foods is associated with a number of health benefits, including&#xD;
      lower risk of cardiovascular disease, breast and prostate cancer, attenuated menopausal&#xD;
      symptoms and prevention of bone loss with age.&#xD;
&#xD;
      In order to investigate the effect of isoflavone on bone mineral density (BMD) and in Taiwan&#xD;
      women with postmenopausal osteopenia, a Taiwan Isoflavone Multicentric Enrollment Study&#xD;
      (TIMS) is designed. Included in the study will be Taiwanese, postmenopausal women aged &gt;45&#xD;
      and &lt; 65 years, menopaused for at least 12 months and less than 10 years. Three medical&#xD;
      centers will participate and enroll 140 women in every center. Inclusion will be on the basis&#xD;
      of a lumbar bone mineral density (BMD) lower than 1 SD compared with young age women (T&#xD;
      score) by DXA. Women with prevalent fractures (any kind of fragility fracture, vertebral or&#xD;
      nonvertebral fracture) are excluded as well as those presenting secondary osteoporosis or&#xD;
      having been treated with medications that could affect bone metabolism. This study is&#xD;
      designed as a 2-year, double-blind, placebo-controlled, two-arm, parallel group study that&#xD;
      randomizes the women to the oral administration of 300 mg isoflavone aglycone/day or placebo.&#xD;
      All patients receive a daily supplement of 600 mg calcium and 300U of Vit D3. The primary&#xD;
      endpoint of the study is to evaluate the effect of isoflavone aglycone on BMD. The secondary&#xD;
      endpoint of the study will be to evaluate the effect of Isoflavone aglycone on the metabolic&#xD;
      indicators of osteoporosis, blood pressure, blood sugar and insulin level, insulin resistance&#xD;
      (HOMA-IR), lipid profile, markers of arthrosclerosis (adiponectin and hsCRP), myocardial&#xD;
      infarction rate, cardiovascular mortality, cerebrovascular accident rate, cerebrovascular&#xD;
      mortality, all cause mortality and symptomatic relief of menopausal syndrome, BMD reading&#xD;
      will be done concomitantly by 3 experts, e.g. one from each participating center. All blood&#xD;
      test and urine examination will be done at one center for control of quality. The blood&#xD;
      count, biochemistry (including: GOT, GPT, BUN, creatinine), mammography, and gynecological&#xD;
      sonography (especially uterus) will be performed to monitor the side effects.&#xD;
&#xD;
      Power calculations have been based on the hypothesis that isoflavone-treated patients would&#xD;
      get 2.5% benefit in BMD than placebo-treated patients in postmenopausal women. Statistical&#xD;
      tests have been designed to have a power of 80%, with a type I error equal to 5%. This study&#xD;
      should verify the hypothesis that isoflavone significantly increase the BMD in Asian&#xD;
      postmenopausal osteopenic women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <completion_date>December 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMD change</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
  </secondary_outcome>
  <enrollment>420</enrollment>
  <condition>Low Bone Density</condition>
  <condition>Osteopenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Soy Isoflavone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The postmenopausal women who menopaused for at least 12 months and less than 10 years.&#xD;
&#xD;
          2. The postmenopausal women aged &gt;45 and &lt; 65 years.&#xD;
&#xD;
          3. For those being done with hysterectomy and age between 50 and 60, with FSH &gt;40 IU/l&#xD;
             and Estradiol &lt; 40 pg/ml.&#xD;
&#xD;
          4. Bone mineral density (BMD) of lumbar spine L2-L4 (AP view) lower than 1 SD compared&#xD;
             with young age women (T score&lt;-1)&#xD;
&#xD;
          5. BMI, above 18.5kg/m2 and below 30 kg/m2&#xD;
&#xD;
          6. Willingness to comply with the protocol and signed the written Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prevalent vertebral, hip or wrist fractures.&#xD;
&#xD;
          2. Secondary osteoporosis, osteomalacia, Paget's disease of bone, multiple myeloma, or&#xD;
             bone metastases.&#xD;
&#xD;
          3. Hormonal replacement therapy (HRT) or SERM within the previous 3 months&#xD;
&#xD;
          4. Phytoestrogen treatment within the previous 3 months&#xD;
&#xD;
          5. Fluoride treatment within the previous 6 months&#xD;
&#xD;
          6. Bisphosphate treatment within the previous 12 months&#xD;
&#xD;
          7. Calcitonin treatment within the previous 6 months&#xD;
&#xD;
          8. Any other treatment affecting the bone mineral density within the previous 6 months&#xD;
&#xD;
          9. Chronic systemic corticosteroid treatment within the previous 6 months&#xD;
&#xD;
         10. History of Gynecological cancer or breast cancer&#xD;
&#xD;
         11. Cervical smear class III or IV, according to the Bethesda system.&#xD;
&#xD;
         12. Undiagnosed vaginal bleeding.&#xD;
&#xD;
         13. Known or suspected estrogen-dependent tumors, fibroids or endometrial polyps&#xD;
&#xD;
         14. Significant or Pathological endometrial hyperplasia&#xD;
&#xD;
         15. Active major psychiatric disorders&#xD;
&#xD;
         16. Alcoholism or drug abuse&#xD;
&#xD;
         17. Known cardiovascular, cerebrovascular or peripheral vascular disorders (e.g.&#xD;
             thrombophlebitis, thromboembolism)&#xD;
&#xD;
         18. Uncontrolled Diabetes with HbA1C &gt; 10%&#xD;
&#xD;
         19. Uncontrolled hypertension with blood pressure &gt; 180/100 mmHg&#xD;
&#xD;
         20. Uncontrolled hypothyroidism&#xD;
&#xD;
         21. Any renal disease with serum creatinine &gt; 2mg/dl&#xD;
&#xD;
         22. Abnormal liver function with S-ALT and S-AST values&gt; 2-fold upper limits&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tong-Yuan Tai, MD &amp; PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHRI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ching-I Chang, MS</last_name>
    <phone>886-02-26534401</phone>
    <phone_ext>27306</phone_ext>
    <email>cichang@nhri.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang-hua Christian Hospital</name>
      <address>
        <city>Chang-hua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Te Tu, MD</last_name>
      <phone>886-4-7009198</phone>
      <email>10836@cch.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>700</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Shang Wu, MD</last_name>
      <phone>886-6-3028119</phone>
      <email>jins@mail.ncku.edu.tw</email>
    </contact>
    <contact_backup>
      <last_name>Chih-Hsing Wu, MD</last_name>
      <phone>886-6-3028119</phone>
      <email>paulo@mail.ncku.edu.tw</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keh-Sung Tsai, MD &amp;PHD</last_name>
      <phone>886-02-23562149</phone>
      <email>kstsaimd@ha.mc.ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>December 5, 2005</study_first_submitted>
  <study_first_submitted_qc>December 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <last_update_submitted>December 5, 2005</last_update_submitted>
  <last_update_submitted_qc>December 5, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2005</last_update_posted>
  <keyword>Post-Menopausal osteopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

